YolTech Therapeutics (尧唐生物)

Shanghai in vivo gene-editing company founded in 2021 that builds its own editors, its own LNPs and its own GMP plant.

1. Core Product / Service

YolTech develops one-time in vivo gene-editing medicines. It has built two platforms in-house [2]:

Editors: high-throughput editor mining and evolution, producing its YolCas and YolBE editors.
Delivery: a non-viral LNP platform designed to reach different tissues.

The company says six programs are in the clinic, the most of any in vivo editing company worldwide; another interview gives five [2][3].

YOLT-201 (ATTR amyloidosis): NMPA clearance March 2024; first patient dosed June 2024. The company describes it as China's first LNP in vivo editing drug in a registrational trial [4].
YOLT-101 (PCSK9 base editing): in the clinic [4].
YOLT-202 (AATD) and YOLT-203 (PH1): reported FDA RMAT designations [4].

2. Target Users & Pain Points

Patients with inherited or chronic liver-driven diseases, such as ATTR, familial hypercholesterolemia and primary hyperoxaluria. Today these need lifelong dosing; a single editing treatment aims to replace it.

3. Competitive Landscape

Player	Positioning	Vs. YolTech
US in vivo editing leaders	CRISPR nuclease and base editors, LNP-delivered	YolTech claims more clinical programs, mainly via Chinese trials
argo-biopharmaceutical	siRNA against some overlapping liver targets	Repeat dosing versus one-time editing
weitao-bio	In vivo CAR-T with LNP-mRNA, founded 2025	Shares LNP know-how; different use
Other Chinese gene-editing biotechs	Several founded in 2021	YolTech has the largest disclosed recent round

4. Unique Observations

Wet-lab and manufacturing model: mostly in-house.
- R&D is at a Shanghai headquarters R&D center [4].
- A Nanjing GMP production base, set up in 2023, supplies its editing drugs [4].
- Construction of an AI-driven editor-evolution lab began in 2024 [4].
- Headcount was about 90 in 2025, per a trade-press report [7]. Lab floor area is not disclosed.
China-first licensing: instead of licensing ex-China rights, it licensed YOLT-101's mainland China rights to Salubris, a domestic cardiovascular company [5][6].
AI collaboration: a reported AI-assisted mRNA R&D collaboration with xtalpi appears only in headlines and is unverified [4].

5. Financials / Funding

Round	Date	Amount	Lead
Angel / A	2021 / 2022	Undisclosed	— [4]
A+	2023 H2	>RMB 100M	— [4]
B	2025-09	>RMB 300M	AstraZeneca-CICC healthcare fund [3]
C	2026-05-29	≈RMB 500M	Zhengxin Valley; existing investors followed [2][3]

Total: dollar-denominated reports put the total through Series B at about US$83M; another database shows US$42M. Including the C round, the total is roughly RMB 1.1B [1].
Salubris (2024-08-27): mainland China rights to YOLT-101. Upfront plus development milestones up to RMB 205M; total up to RMB 1.035B [5][6].

6. People & Relationships

Founder & CEO: 吴宇轩 (Wu Yuxuan), with prior work at East China Normal University, Harvard and Boston Children's Hospital [7].
Investors: Zhengxin Valley, AstraZeneca-CICC fund, Songhe Capital, K2VC-affiliated fund (险峰淇云), Yuanyi, Tianchuang [2][3].
Partner: Salubris (信立泰).
Peers: argo-biopharmaceutical, full-life-technologies.